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Background: Bronchial asthma influences some chronic diseases such as coronary heart disease, diabetes mellitus,
and hypertension, but the impact of asthma on vital diseases such as chronic kidney disease is not yet verified. This
study aims to clarify the association between bronchial asthma and the risk of developing chronic kidney disease.
Methods: The National Health Research Institute provided a database of one million random subjects for the study.
A random sample of 141 064 patients aged ≥18 years without a history of kidney disease was obtained from the
database. Among them, there were 35 086 with bronchial asthma and 105 258 without asthma matched for sex
and age for a ration of 1:3. After adjusting for confounding risk factors, a Cox proportional hazards model was used
to compare the risk of developing chronic kidney disease during a three-year follow-up period.
Results: Of the subjects with asthma, 2 196 (6.26%) developed chronic kidney disease compared to 4 120 (3.91%)
of the control subjects. Cox proportional hazards regression analysis revealed that subjects with asthma were more
likely to develop chronic kidney disease (hazard ratio [HR]: 1.56; 95% CI: 1.48-1.64; p < 0.001). After adjusting for sex,
age, monthly income, urbanization level, geographic region, diabetes mellitus, hypertension, hyperlipidemia, and
steroid use, the HR for asthma patients was 1.40 (95% CI: 1.33-1.48; p = 0.040). There was decreased HRs in steroid
use (HR: 0.56; 95% CI: 0.62-0.61; p < 0.001) in the development of chronic kidney disease. Expectorants,
bronchodilators, anti-muscarinic agents, airway smooth muscle relaxants, and leukotriene receptor antagonists may
also be beneficial in attenuating the risk of chronic kidney disease.
Conclusions: Patients with bronchial asthma may have increased risk of developing chronic kidney disease. The
use of steroids or non-steroidal drugs in the treatment of asthma may attenuate this risk.
Keywords: Bronchial asthma, Chronic kidney diseases, National Health Insurance Research DatasetBackground
Bronchial asthma is a chronic inflammatory lung disease
with exacerbations, which may be a factor in its morbidity
and mortality. The Global Initiative for Asthma (GINA)
2004 report states that nearly 300 million people suffer
from asthma worldwide [1,2] and asthmatic patients in
Taiwan account for 2.6% [1]. The report also states that
urban living [3] and lower income [1] are risk factors for
asthma and that the environment, regardless of indoor or
outdoor, also impacts on patients with asthma [3].* Correspondence: pierrens@mail.ndmctsgh.edu.tw
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unless otherwise stated.Bronchial asthma also influences other chronic dis-
eases involving the cardiovascular and carbohydrate
metabolism systems. Patients with asthma have higher
risks of coronary heart disease (CHD) [4], diabetes mel-
litus [5], and hypertension [3], although the impact of
asthma on other vital organs are not yet verified.
Chronic kidney disease (CKD) is a major global problem.
Patients who progress to end-stage renal disease (ESRD)
need dialysis or transplantation, which cause heavy medico-
economic burden. In 2010, there were 651 000 patients
with ESRD in the United States whose care cost around US
$28.3 billion. In Taiwan, there were approximately 11.93%
with CKD, about one eighth for Taiwanese. Recent studies
have found that predictors of CKD include metabolic syn-
drome [6], obesity [7], vascular diseases [8], hyperlipidemiaLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Huang et al. BMC Pulmonary Medicine 2014, 14:80 Page 2 of 8
http://www.biomedcentral.com/1471-2466/14/80[9] and cardiovascular diseases [10], hypertension [11],
diabetes mellitus [11], and heart disease [12] (OR: 1.95
[1.32-2.87]). However, there is no report on the associ-
ation between asthma and kidney diseases.
This study used the Taiwan National Health Insurance
Research Database (NHIRD) to determine the association
of asthma and CKD in a three-year follow-up period
(2003–2007). The National Health Insurance (NHI) Pro-
gram, began in Taiwan in 1995, had enrolled 22 928 190
people as of June 2009, exceeding 99% of the population.
The NHI also has a contract with 97% of the medical
providers in Taiwan [13]. The diagnostic coding used
for the NHI in Taiwan is according to the International
Classification of Diseases, 9th Revision, Clinical Modifi-
cation (ICD-9-CM) diagnostic criteria [14]. Each diagno-
sis of asthma was made by board-certified internists,
clinical immunologists, pulmonologists, or other medical
experts. The Bureau of National Health Insurance ran-
domly reviews the charts of 1 per 100 ambulatory and 1
per 20 in-patient claim cases to verify the accuracy of
the diagnosis [15]. In Taiwan, the diagnosis of CKD fol-
lows the criteria of “Kidney Disease: Improving Global
Outcomes (KDIGO)”. CKD is defined as kidney dam-
age as albumin-to-creatinine ratio >30 mg/g in two of
three spot urine specimens or glomerular filtration rate
(GFR) <60 mL/min/1.73 m2 for 3 months or more,
irrespective of the cause [16]. The diagnosis of bron-
chial asthma bases on characteristic clinical history
such as intermittent breathlessness, wheezing, trouble-
some night time cough and chest tightness, aided by
lung function tests in some cases [17,18], which is




This research used the Longitudinal Health Insurance
Database (LHID) 2005 derived from NHI program [21].
The LHID covered more than 25 million Taiwanese, or ap-
proximately 98% of the citizens [22] who lived in Taiwan
more than four months.
The longitudinal database was a subset of the National
Health Insurance Research Database (NHIRD) and con-
sisted of 1 million Taiwanese enrolled in the database in
2005 [23]. It contained home care visits, ambulatory
care, out-patient care, prescription drugs, and medical
record that was encoded by using the International
Classification of Disease, 9- revision, Clinical Modification
(ICD-9-CM) [24].
The Internal Review Board encrypted the database to
remove any personal identification before the release of
the dataset for public access. In this study, both the
study and control cohorts had no significant difference
in sex and age distribution and were selected randomlyfrom LHID2005. Patients aged ≥18 years old who were
first diagnosed with asthma (ICD-9-CM: 493) between
January 1, 2004 and the end of 2007 were included in
the study cohort and their date of diagnosis was their
index date. The control cohort consists of the patients
having no history of bronchial asthma or CKD from
2000 to 2010. These patients were randomly chosen by
matching the gender and age of the study cohort with a
ratio of 1:3. In addition, the middle date of the same
month with that of the index date in the study cohort
was assigned to the index date of the corresponding pa-
tient in the control cohort.
The patients were followed-up for three years from
the index date until the patient was diagnosed with CKD
(ICD-9-CM: 580, 581, 582, 583, 584, 585, 586, 587, 588,
589, 753, 403, 404, 2504, 2741, 4401, 4421, 4473, 5724,
6421, and 6462) or until the end of 2010. Patients with
missing data were excluded, as well as those with CKD
before asthma. The final study and control cohorts had
35 086 and 105 258 patients, respectively. The follow-up
interval of the subjects and controls for developing
chronic kidney disease during is in a three-year follow-
up period.
The covariates considered included diabetes mellitus
(ICD-9-CM 250, 357.2, 362.0x, and 366.41), hyperten-
sion (ICD-9-CM 362.11, 401.x-405.x, and 437.2), hyper-
lipidemia (ICD-9-CM 272.x), heart disease (ICD-9-CM
410–429 and A codes A270, A279-A281, and A289) and
obesity (ICD codes: 278.00, 278.01, 278.02, 278.03). Data
on intake of steroids, anti-asthma drugs, and other drugs
like expectorants, bronchodilators, anti-muscarinic agents,
and airway smooth muscle relaxants, were collected.Ethical approval
The Institutional Review Board of Changhua Christian
Hospital approved the study (IRB/CCH, No. 121007).Statistical analysis
The SPSS software version 19.0 (SPSS Inc., Chicago, IL,
USA) was used for all statistical analyses. The chi-square
test was used for the descriptive analyses concerning distri-
bution of population, level of urbanization (i.e., provinces,
counties, districts, and urban villages), geography (northern,
central, southern, and eastern), income (<18000, between
18000 and 35000, and ≥35000), co-morbidities (e.g.,
diabetes, hypertension, hyperlipidemia, and heart disease)
and medications.
Multiple logistic regression analyses were performed
to estimate hazard ratio (HR) and 95% confidence inter-
vals (CIs) of bronchial asthma associated with CKD after
controlling for age, sex, levels of urbanization and in-
come. Statistical significance was set at p < 0.05.
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The asthma subjects (n = 35086) and non-asthmatic con-
trols (n = 105258) both had a mean age of 47.72 years
(Table 1). There was no significant difference in distribu-
tions of sex, age, urbanization, geography, and economic
status between the two groups. The patients with asthma
had higher prevalences of diabetes mellitus, hypertension,
hyperlipidemia, heart disease and obesity compared to theTable 1 Distribution of sex, age, urbanization, geography,
income, co-morbidity, and medication of individuals with
asthma and without asthma




n = 105258 p value
Age, yr, mean (SD) 47.72 ± 17.73 47.72 ± 17.73 1
Sex
Male 15460 (44.1%) 46380 (44.1%)
Female 19626 (55.9%) 58878 (55.9%)
Age Group 1
18-29 6534 (18.6%) 19602 (18.6%)
30-39 6307 (18.0%) 18921 (18.0%)
40-49 6411 (18.3%) 19233 (18.3%)
50-59 5751 (16.4%) 17253 (16.4%)
≥60 10083 (28.7%) 30249 (28.7%)
Urbanization <0.05
Provinces 8777 (25.0%) 28167 (26.8%)
Counties 2568 (7.3%) 8464 (8.0%)
Districts 8988 (25.6%) 26504 (25.2%)
Urban villages 14753 (42.0%) 42123 (40.0%)
Geography <0.05
North 18559 (52.9%) 52460 (49.8%)
Central 6502 (18.5%) 18653 (17.7%)
South 9151 (26.1%) 31605 (30.0%)
East 874 (2.5%) 2540 (2.4%)
Income <0.05
<18000 15880 (45.3%) 49785 (47.3%)
18000-35000 14363 (40.9%) 40763 (38.7%)
>35000 4843 (13.8%) 14710 (14.0%)
Co-morbidity
Diabetes 1457 (4.2%) 2811 (2.7%) <0.05
Hypertension 2472 (7.0%) 4467 (4.2%) <0.05
Hyperlipidemia 1629 (4.6%) 2983 (2.8%) <0.05
Heart Disease 2115 (6.0%) 3152 (3.0%) <0.05
Obesity 91 (0.3%) 105 (0.1%) <0.05
Medication
Steroids 19720 (56.2%) 24373 (23.2) <0.05controls. More than 50% of the asthma patients (n = 19720,
56.2%) used steroids as treatment for asthma.
On Kaplan Meier (KM) survival curve, two years would
have produced significant CKD (p < 0.001) (Figure 1). Thus,
a follow-up time of three years would have been more suit-
able in this study.
Subjects with asthma (2196 in 35086) were more likely
have CKD compared to controls (4125 in 105258) (HR:
1.56, 95% CI: 1.48-1.64; p < 0.001) (Table 2).
After adjusting for sex, age, andco-morbidities, includ-
ing obesity, patients with asthma developed CKD (HR:
1.13 [1.07-1.19], p < 0.001) compared to HR before the
adjustments (HR: 1.56 [1.48-1.64], p < 0.001) (Table 3).
Male asthma patients were more likely to have CKD
than female asthma patients (HR: 1.16 [1.11-1.22], p <
0.001). Patients with co-morbidities, including diabetes
mellitus (HR: 1.42 [1.33-1.51], p < 0.001), hypertension
(HR: 15.52 [14.18-16.99], p < 0.001), hyperlipidemia (HR =
1.55 [1.45-1.65], p < 0.001), and heart disease (HR: 1.86
[1.71-1.98], p < 0.001), had high risks of CKD. Hypertension
was the co-morbidity with the highest risk of developing
CKD. After adjusting for steroid treatment, the adjusted
HR of developing CKD was 1.40 in asthma subjects.
Patients who used steroids had lower risk of developing
CKD (HR: 0.50 [0.47-0.53], p < 0.001).
Asthma patients taking steroids were compared to pa-
tients not taking steroids (Table 4). In the subgroup with
steroid treatment (n = 26236), 1038 (3.96%) developed
CKD in the longitudinal follow-up within three years. In
the subgroup without steroid treatment (n = 8850), 1158
(13.08%) developed CKD in the same follow-up period.
The HR of the steroid treatment subgroup was 0.56
(95% CI: 0.522-0.61, p < 0.001) after adjusting for co-
morbidities of diabetes mellitus, hypertension, hyperlip-
idemia, and heart disease. Steroid treatment attenuated
the risk of developing CKD (HR: 0.56, 95% CI: 0.62-0.61;
p < 0.001) after adjusting for co-morbidities (Table 5).
Non-steroidal drugs for treatment of asthma were
grouped into five classes: expectorants, bronchodilators,
anti-muscarinic agents, airway smooth muscle relaxants,
and leukotriene receptor antagonists. After adjusting
for co-morbidities, all of these drugs attenuated the
HRs of developing CKD. Regardless of adjustments for
co-morbidities and steroid use, expectorants and bron-
chodilators attenuated the risk for developing CKD.
Discussion
This prospective case control study analyzed the rela-
tionship between asthma and CKD (HR: 1.56 [1.48-
1.64], p < 0.001) using population-based data (LHID) in
Taiwan. In the dataset, patients first diagnosed with
asthma and without CKD between 2000 and 2003 were
analyzed. The Kaplan-Meier survival curve showed a
time-to-event of two years, such that patients with
Figure 1 Survival curves of patients with and without asthma.
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(p < 0.001). As such, a follow-up time of three years
was a sufficient follow-up period for this study.
Most researches report that patients with older age
have increased risk of developing CKD [25]. Moreover,
patients with hypertension [3], heart disease [4], diabetes
[5], hyperlipidemia [9] and obesity [26-28] also have high
risk of CKD. However, after adjusting for sex, age, and
these co-morbidities, subjects with asthma still have sig-
nificant and independent high risk of CKD (HR: 1.13
[1.07-1.19], p < 0.001).
Except for some rare case reports [29,30], there are
very few studies investigating the interactions between
asthma and CKD. To date, this is the first study to show
that asthma patients are prone to developing CKD inTable 2 Individuals with and without asthma as a
predictor of chronic kidney disease, identified by Cox
regression





With chronic kidney disease 2196 4125
Without chronic kidney disease 32890 101106
Hazard ratio 1.56 (1.48-1.64)‡
‡p < 0.001 for comparison between patients with asthma and the controls.comparison to non-asthma patients. Some patients with
exercise-induce asthma seldom exercise [31] and several
researches report that aerobic exercise may improve
CKD [32,33]. Limited exercise may be one of the reasons
for the higher risk of CKD in some types of asthma from
the perspective of health behaviours.
Recently, one study of 2354 asthma patients from a
retrospective cohort in China indicates that there is 9.6%
incidence of CKD in a period of six-year follow-up, in
which the group of persistent asthma has independent,
higher risk of CKD than the non-persistent group. In
addition, patients with three traits together of long his-
tory of asthma > 20 years, having no well-controlled
asthma and persistent stage of asthma, have significant
risk as high as OR = 3.39 (95% CI 1.36–8.73), compared
to patients without these traits [34]. This study finds an
association between asthma and later CKD using a large
cohort comprising asthma subjects (n = 35086) and non-
asthma controls (N = 105258) in a three-year period of
follow-up. Steroid and other medication treatment might
decrease the risk of CKD associated with asthma. The
suggestion of the two studies is similar that the value of
well-controlled asthma is high not only to preserve the
respiratory function but also to benefit other organs.
Furthermore, one common pathophysiology, inflamma-
tion, may provide some preliminary explanations. Recent
Table 3 Independent predictors of chronic kidney





Asthma 1.13 (1.07-1.19)‡ 1.40 (1.33-1.48)‡
Female reference reference
Male 1.16 (1.11-1.22)‡ 1.16(1.10-1.22)‡
Age group
18-29 reference reference
30-39 1.51 (1.30-1.76)‡ 1.52 (1.31-1.77)‡
40-49 1.91 (1.66-2.19)‡ 1.99 (1.73-2.28)‡
50-59 2.02 (1.76-2.31)‡ 2.14 (1.86-2.45)‡
≥60 2.08 (1.83-2.38)‡ 2.23 (1.96-2.55)‡
Co-morbidity
Diabetes 1.42 (1.33-1.51)‡ 1.42 (1.33-1.52)‡
Hypertension 15.52 (14.18-16.99)‡ 15.24 (13.92-16.68)‡
Hyperlipidemia 1.55 (1.45-1.65)‡ 1.53 (1.43-1.64)‡
Heart Disease 1.84 (1.71-1.98)‡ 1.92 (1.78-2.06)‡
Obesity 1.3 (1.07-1.58)† 1.39 (1.14-1.69)‡
Medication
Steroid (used in 56.2% asthma
subjects)
0.50(0.47-0.53)‡
Note: †p < 0.05 for comparison between patients with asthma and without
asthma; ‡p < 0.001 for comparison between patients with asthma and
without asthma.
HR*, each variable was adjusted for every other variable listed except
for medication.
HR**, each variable was adjusted for every other variable listed.
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(NLRP3) inflammasome may also provide a potential
link between asthma and CKD. The NLRP3 inflamma-
some contributes to the progression of CKD by pro-
moting renal inflammation [35] and plays a role in the
human rhinovirus-related primary bronchial cell in-
flammation [36].Table 4 Steroid use in patients with asthma as a predictor
of chronic kidney disease, by Cox regression analysis











Hazard ratio 0.74 (0.70-0.78)‡
Hazard ratio* 0.56 (0.53-0.589)‡
Note: ‡p < 0.001 for comparison between patients who used steroids and
those who did not.
Hazard Ratio*, Adjusted for diabetes, hypertension, hyperlipidemia, and
heart disease.In our study, the recruited subjects with asthma are in
older age as 47.72 ± 17.73 years. Several studies showed
that asthma could develop at age after childhood, adoles-
cence or young adult stage, and several genetic factors, air
pollution or obesity could be related to later onset of bron-
chial asthma [37-39]. One study of 504 asthmatic patients
(303 males and 201 females) in Taiwan indicates that 29%
developed asthma at age 25–44 years old, 21% developed
asthma at age 45–65 years old, and 8% developed asthma
beyond age of 64 [40]. The recent study indicates that the
age of onset asthma is 45.4 ± 10.4 years, which is also simi-
lar to our study of 47.72 ± 17.73 years [34].
Aside from co-morbidities, drugs used in the treat-
ment of asthma also influence the development of
CKD. These include steroids and non-steroidal anti-
asthma drugs. In this study, 56.2% of patients with
asthma take steroids. Steroid use is associated with
lower risk of CKD after adjusting for sex, age, and co-
morbidities. Steroids can decrease inflammatory reac-
tions and are used to treat inflammatory diseases. After
adjusting for steroid use, the HR of asthma increased,
indicating that asthma directly impacts on CKD. This
also supports the hypothesis that chronic inflammation
in asthma patients may be related to the higher risk of
developing CKD. Proper steroid treatment for asthma
may significantly reduce the risk of CKD.
Non-steroidal drugs used for asthma were also ana-
lyzed. In this study cohort, only patients with asthma
were included. Classes of non-steroidal drugs were
expectorants, bronchodilators, anti-muscarinic agents,
airway smooth muscle relaxants, and leukotriene re-
ceptor inhibitors. After adjusting for diabetes, hyper-
tension, hyperlipidemia, and heart disease, all of these
non-steroidal drugs could attenuate the development
of CKD. Nonetheless, regardless of adjustments for co-
morbidities or steroid use, expectorants and bronchodila-
tors can attenuate the risk for CKD. Although leukotriene
receptors have anti-inflammatory properties, they have
low potential of attenuating the risk for CKD [41].
However, the biological mechanisms involved warrant
further investigations.
This study has some limitations. Although the LHID
2005 in Taiwan has benefits in analyzing disease and is
commonly used in research because of its reliability, it
has some limitations. First, the selected data might ex-
clude samples because of missing data, making the
data here incomplete. Second, the diagnostic code is
made by doctors. However, sometimes the code is not
final, especially in ambulatory settings. Third, the
presence of diseases was base on ICD-9-CM. The pre-
cision of this system and its impact on outcome could
not be determined. Furthermore, no information about
cigarette smoking, which is a risk factor of CKD [42], is
available in the NHIRD database. However, we have
Table 5 Hazard ratios (HRs) of asthma patients by drug used compared to patients without drug use
Variables n (%) HR (95% CI) HR* (95% CI) HR** (95% CI) With steroid HR*** (95% CI) Without steroid HR**** (95% CI)
Steroid
Yes (n = 19720) 1038 (5.3%) 0.68 (0.62-0.73)‡ 0.56 (0.52-0.61)‡ N/A N/A N/A
No (n = 15366) 1158 (7.5%)
Expectorant
Yes (n = 6818) 339 (5.0%) 0.74 (0.66-0.83)‡ 0.59 (0.53-0.67)‡ 0.63 (0.54-0.74)‡ 0.65 (0.55-0.78)‡ 0.64 (0.57-0.72)‡
No (n = 28268) 1857 (6.6%)
Bronchodilators
Yes (n = 19933) 1157 (5.8%) 0.84 (0.77-0.91)‡ 0.67 (0.61-0.72)‡ 0.78 (0.68-0.89)‡ 0.78 (0.69-0.88)‡ 0.78 (0.71-0.85)‡
No (n = 15153) 1039 (6.9%)
Anti-muscarinic agents
Yes (n = 4298) 264 (6.1%) 1.00 (0.88-1.14) 0.72 (0.63-0.82)‡ 0.87 (0.75-1.01) 0.86 (0.64-1.14) 0.87 (0.76-0.99)‡
No (n = 30788) 1932 (6.3%)
Airway smooth relaxant
Yes (n = 19222) 1245 (6.5%) 1.07 (0.99-1.17) 0.75 (0.69-0.82)‡ 0.88 (0.77-1.02) 0.91 (0.81-1.03) 0.90 (0.82-0.99)†
No (n = 15864) 951 (6.0%)
Leukotriene receptor antagonist
Yes (n = 1432) 46 (3.2%) 0.48 (0.36-0.65)‡ 0.59 (0.44-0.79)‡ 0.72 (0.52-1.00) 0.62 (0.32-1.20) 0.69 (0.52-0.93)†
No (n = 33654) 2150 (6.4%)
Note: HR*, each factor was adjusted for diabetes, hypertension, hyperlipidemia, and heart disease.
CI, confidence interval; n (%), number of participants with CKD and% of participants.
†p < 0.05 for comparison between patients with asthma and without asthma; ‡p < 0.001 for comparison between patient with asthma and without asthma.
Hazard ratios (HRs) of asthma patients by drug used. In each drug, the HR was compared with patients without drug. (a) Crude HR (95% CI) for each drug. (b) HR *(95% CI) for each drug, adjusted for co-morbidities.
(c) Patients with steroid HR **(95% CI) for each drug, adjusted for co-morbidities. (d) Patients without steroid use HR ***(95% CI) for each drug, adjusted for co-morbidities. (e) HR **** (95% CI) for each drug, adjusted
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mellitus, hypertension, hyperlipidemia, and obesity.
Conclusions
Asthma patients have higher risk of developing CKD.
Although interactions between asthma and CKD are still
unclear, behavioural or biological factors such as limited
exercise, inflammation, and other unknown factors can
contribute to the interactions between asthma and
kidney diseases. Steroids and some non-steroidal anti-
asthma drugs can attenuate this risk and the proper
medical treatment for asthma may be beneficial in redu-
cing the risk of CKD.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
NST conceived of the study, participated in its design and coordination, data
interpretation and drafted the manuscript. HLH participated in the design of
the study, data interpretation, performed the statistical analysis, data
collection and drafting of the manuscript. SYH participated in the design of
the study and participated in data interpretation. CHL participated in the
design of the study, data interpretation and drafting of the manuscript. FYC
participated in the design of the study, literature search, data collection, and
performed the statistical analysis. LPC participated in data collection and
data interpretation. HCL and WLC participated in the design of the study
and data interpretation. All authors have read and approved the final
manuscript.
Acknowledgements
This work was supported by National Science Council of Taiwan under the
contract number NSC-101-2627-B-009-003, and “Center for Bioinformatics
Research of Aiming for the Top University Program” of the National Chiao Tung
University and Ministry of Education, Taiwan, R.O.C. for the project 102 W962.
This work was also supported in part by the UST-UCSD International Center of
Excellence in Advanced Bioengineering sponsored by the Taiwan National
Science Council I-RiCE Program under Grant Number: NSC-101-2911-I-009-101.
Authors thank Ms Wei-Shan Jessie Chiang for her assistance in the
administrative work and proofreading of the manuscript.
Author details
1Institute of Bioinformatics and Systems Biology, National Chiao Tung
University, Hsinchu, Taiwan. 2Department of Biological Science and
Technology, National Chiao Tung University, Hsinchu, Taiwan. 3Department
of Surgery, Division of Neurosurgery, National Taiwan University Hospital
Hsin-Chu Branch, Hsinchu City, Taiwan. 4Department of Psychiatry, Tri-Service
General Hospital, School of Medicine and Student Counseling Center, National
Defense Medical Center, #325, Sec 2, Cheng-Gong RdNei- Hu District, Taipei City,
Taiwan.
Received: 31 October 2013 Accepted: 6 May 2014
Published: 8 May 2014
References
1. Masoli M, Fabian D, Holt S, Beasley R, Global Initiative for Asthma P: The
global burden of asthma: executive summary of the GINA Dissemination
Committee report. Allergy 2004, 59(5):469–478.
2. Mueller NT, Koh WP, Odegaard AO, Gross MD, Yuan JM, Pereira MA: Asthma
and the risk of type 2 diabetes in the Singapore Chinese Health Study.
Diabetes Res Clin Pract 2013, 99(2):192–199.
3. Johnson M, Nriagu J, Hammad A, Savoie K, Jamil H: Asthma, Environmental
Risk Factors, and Hypertension Among Arab Americans in Metro Detroit.
J Immigr Minor Healt 2010, 12(5):640–651.
4. Iribarren C, Tolstykh IV, Miller MK, Sobel E, Eisner MD: Adult Asthma and
Risk of Coronary Heart Disease, Cerebrovascular Disease, and HeartFailure: A Prospective Study of 2 Matched Cohorts. Am J Epidemiol 2012,
176(11):1014–1024.
5. Ehrlich SF, Quesenberry CP, Van Den Eeden SK, Shan J, Ferrara A: Patients
Diagnosed With Diabetes Are at Increased Risk for Asthma, Chronic
Obstructive Pulmonary, Disease, Pulmonary Fibrosis, and Pneumonia but
Not Lung Cancer. Diabetes Care 2010, 33(1):55–60.
6. Chen W, Liu Q, Wang H, Chen W, Johnson RJ, Dong X, Li H, Ba S, Tan J,
Luo N, Liu T, He H, Yu X: Prevalence and risk factors of chronic kidney
disease: a population study in the Tibetan population. Nephrol Dial
Transplant 2011, 26(5):1592–1599.
7. Kawashima M, Wada K, Ohta H, Terawaki H, Aizawa Y: Association between
asymptomatic hyperuricemia and new-onset chronic kidney disease in
Japanese male workers: a long-term retrospective cohort study. BMC
Nephrol 2011, 12(31). doi: 10.1186/1471-2369-12-31.
8. Zhang QL, Brenner H, Koenig W, Rothenbacher D: Prognostic value of
chronic kidney disease in patients with coronary heart disease: Role of
estimating equations. Atherosclerosis 2010, 211(1):342–347.
9. Post JB, Jegede AB, Morin K, Spungen AM, Langhoff E, Sano M: Cognitive
Profile of Chronic Kidney Disease and Hemodialysis Patients without
Dementia. Nephron Clin Pract 2010, 116(3):C247–C255.
10. Edwards NC, Ferro CJ, Kirkwood H, Chue CD, Young AA, Stewart PM, Steeds
RP, Townend JN: Effect of Spironolactone on Left Ventricular Systolic and
Diastolic Function in Patients With Early Stage Chronic Kidney Disease.
Am J Cardiol 2010, 106(10):1505–1511.
11. Ooi QL, Tow FKNFH, Deva R, Alias MA, Kawasaki R, Wong TY, Mohamad N,
Colville D, Hutchinson A, Savige J: The Microvasculature in Chronic Kidney
Disease. Clin J Am Soc Nephro 2011, 6(8):1872–1878.
12. Ryoo JH, Kim SG, Suh BS, Kim DI, Park SK: Relationship between Chronic
Kidney Disease and Risk of Coronary Heart Disease in Korean Men.
J Korean Med Sci 2011, 26(6):753–758.
13. Ho Chan W: Taiwan’s healthcare report 2010. EPMA J 2010, 1(4):563–585.
14. Chinese Hospital Association: ICD-9-CM English-Chinese Dictionary. Taipei,
Taiwan: Chinese Hospital Association Press; 2000.
15. Bureau of National Health Insurance Regulations. http://www.nhi.gov.tw/
resource/bulletin/421_0890036465-19.doc.
16. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, De Zeeuw
D, Hostetter TH, Lameire N, Eknoyan G: Definition and classification of
chronic kidney disease: a position statement from Kidney Disease:
Improving Global Outcomes (KDIGO). Kidney Int 2005, 67(6):2089–2100.
17. Yeh KW, Chiang LC, Chen SH, Huang JL: Survey of the clinical practice of
physicians in the management of asthma in Taiwan. Asian Pac J Allergy
Immunol 2006, 24(1):1–8.
18. Yeh KW, Chiang LC, Huang JL: Epidemiology and current status of asthma
and associated allergic diseases in Taiwan- ARIA Asia-Pacific Workshop
report. Asian Pac J Allergy Immunol 2008, 26(4):257–264.
19. National Institutes of Health NH, Lung, and, Institute B: Diagnosis and
classification. In Global Strategy for Asthma Management and Prevention.
Bethesda, MD, USA: National Institutes of Health, National Heart, Lung, and
Blood Institute; 2002:67–79.
20. Global Initiative for Asthma Program: Global Strategy for Asthma
Management and Prevention: 2012 Update. http://www.ginasthma.org/
documents/5/documents_variants/37.
21. Lin LY, Lee CH, Yu CC, Tsai CT, Lai LP, Hwang JJ, Chen PC, Lin JL: Risk
factors and incidence of ischemic stroke in Taiwanese with nonvalvular
atrial fibrillation-A nation wide database analysis. Atherosclerosis 2011,
217(1):292–295.
22. Chiang YY, Lin HW: Association between psoriasis and chronic obstructive
pulmonary disease: a population-based study in Taiwan. J Eur Acad Dermatol
2012, 26(1):59–65.
23. Chung SD, Lin HC: Increased Risk of Benign Prostatic Enlargement
Among Patients With Liver Cirrhosis: A Nationwide Population-Based
Study. J Androl 2011, 32(2):159–164.
24. Lin HY, Lai JI, Lai YC, Lin PC, Chang SC, Tang GJ: Acute renal failure in
severe pancreatitis: A population-based study. Upsala J Med Sci 2011,
116(2):155–159.
25. Quon BS, Mayer-Hamblett N, Aitken ML, Smyth AR, Goss CH: Risk Factors
for Chronic Kidney Disease in Adults with Cystic Fibrosis. Am J Resp Crit
Care 2011, 184(10):1147–1152.
26. Wickens KBD, Friezema A, Rhodius R, Bone N, Purdie G, Crane J: Obesity
and asthma in 11–12 year old New Zealand children in 1989 and 2000.
Thorax 2005, 60(1):7–12.
Huang et al. BMC Pulmonary Medicine 2014, 14:80 Page 8 of 8
http://www.biomedcentral.com/1471-2466/14/8027. Lessard A, Turcotte H, Cormier Y, Boulet LP: Obesity and asthma: a specific
phenotype? Chest 2008, 134(2):317–323.
28. Figueroa-Munoz JI, Chinn S, Rona RJ: Association between obesity and
asthma in 4–11 year old children in the UK. Thorax 2001, 56(2):133–137.
29. Dubchak I, Gomolka M, Niemczyk S: Rapid course of Churge-Strauss
syndrome–since appearance of asthma till development of renal failure
and neurological complication. Pol Merkur Lekarski 2012, 32(189):170–172.
30. Aarset H, Aasarod K, Bergan U, Angelsen A: Acute renal infarction in a
woman with slight asthma. Nephrol Dial Transplant 2001, 16(8):1711–1712.
31. Small I, Moreira A, Couto M: Practical approach to managing exercise-induced
asthma in children and adults. Prim Care Respir J 2013, 22(1):126–129.
32. Moinuddin I, Leehey DJ: A comparison of aerobic exercise and resistance
training in patients with and without chronic kidney disease. Adv Chronic
Kidney Dis 2008, 15(1):83–96.
33. Leehey DJ, Moinuddin I, Bast JP, Qureshi S, Jelinek CS, Cooper C, Edwards
LC, Smith BM, Collins EG: Aerobic exercise in obese diabetic patients with
chronic kidney disease: a randomized and controlled pilot study.
Cardiovasc Diabetol 2009, 8:62.
34. Liu DW, Zhen XG, Liang Y, Jing XG, Zhang TS, Zhang GJ, Liu ZS: Persistent
asthma increases the risk of chronic kidney disease: a retrospective
cohort study of 2354 patients with asthma. Chin Med J (Engl) 2013,
126(21):4093–4099.
35. Vilaysane A, Chun J, Seamone ME, Wang W, Chin R, Hirota S, Li Y, Clark SA,
Tschopp J, Trpkov K, Hemmelgarn BR, Beck PL, Muruve DA: The NLRP3
inflammasome promotes renal inflammation and contributes to CKD.
J Am Soc Nephrol 2010, 21(10):1732–1744.
36. Triantafilou K, Kar S, van Kuppeveld FJ, Triantafilou M: Rhinovirus-Induced
Calcium Flux Triggers NLRP3 and NLRC5 Activation in Bronchial Cells.
Am J Respir Cell Mol Biol 2013, 49(6):923–934.
37. Jeebhay MF, Ngajilo D, le Moual N: Risk factors for nonwork-related
adult-onset asthma and occupational asthma: a comparative review.
Curr Opin Allergy Clin Immunol 2014, 14(2):84–94.
38. Le Moual N, Carsin AE, Siroux V, Radon K, Norback D, Toren K, Olivieri M,
Urrutia I, Cazzoletti L, Jacquemin B, Benke G, Kromhout H, Mirabelli MC,
Mehta AJ, Schlünssen V, Sigsgaard T, Blanc PD, Kogevinas M, Antó JM, Zock
JP: Occupational exposures and uncontrolled adult-onset asthma in the
European Community Respiratory Health Survey II. Eur Respir J 2014,
43(2):374–386.
39. Lee YL, Hsiue TR, Lee CH, Su HJ, Guo YL: Home exposures, parental atopy,
and occurrence of asthma symptoms in adulthood in southern Taiwan.
Chest 2006, 129(2):300–308.
40. Hsu JY, King SL, Kuo BI, Chiang CD: Age of onset and the characteristics of
asthma. Respirology 2004, 9(3):369–372.
41. Papierniak ES, Lowenthal DT, Harman E: Novel Therapies in Asthma:
Leukotriene Antagonists, Biologic Agents, and Beyond. Am J Ther 2013,
20(1):79–103.
42. Noborisaka Y, Ishizaki M, Yamazaki M, Honda R, Yamada Y: Elevated Serum
Gamma-Glutamyltransferase (GGT) Activity and the Development of
Chronic Kidney Disease (CKD) in Cigarette Smokers. Nephro-urology
monthly 2013, 5(5):967–973.
doi:10.1186/1471-2466-14-80
Cite this article as: Huang et al.: Bronchial asthma is associated with
increased risk of chronic kidney disease. BMC Pulmonary Medicine
2014 14:80.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
